Protalix BioTherapeutics Announces Oral GCD Data to be Presented at WORLD Symposium 2014

[GlobeNewswire] – CARMIEL, Israel — Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) announced today that phase I clinical trial data for oral GCD (PRX-112) for the treatment of Gaucher disease will be presented by Professor … more

View todays social media effects on PLX

View the latest stocks trending across Twitter. Click to view dashboard

See who Protalix is hiring next, click here to view